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Abstract
Background Systematic, well-controlled clinical trials of
botulinum toxin type A (BoNTA) in diverse patient popula-
tionsareneeded.Theaimofthisstudywastocharacterizethe
safety and efﬁcacy of 10-U and 20-U BoNTA doses versus
placebo for treating glabellar lines in Japanese subjects.
Methods A 16-week, multicenter, double-blind, random-
ized, placebo-controlled trial comparing 10 or 20 U of
BoNTA versus placebo in 142 Japanese subjects with
glabellar lines of at least moderate severity at maximal
contraction. The primary efﬁcacy endpoint was physician-
rated line severity at maximal contraction 4 weeks after
treatment. Secondary efﬁcacy endpoints included physi-
cian/subject ratings and estimates of the effect’s duration.
Results Response rates by physician-rated line severity at
maximal contraction (week 4) were 86.4% (10 U), 88.6%
(20 U), and 0% (placebo, p\0.001). Line severity at
maximal contraction in each BoNTA group (p\0.001)
improved signiﬁcantly from baseline at each visit. BoNTA
and placebo differed signiﬁcantly on all other efﬁcacy
measures. Mean duration of effect was 9.4 weeks in the 20-
U group and 7.9 weeks in the 10-U BoNTA group. No
serious adverse events occurred.
Conclusion Doses of BoNTA of 10 and 20 U are effec-
tive and safe for treating glabellar lines in Japanese
subjects, and the 20-U dose provides greater efﬁcacy and
longer duration of effect.
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Botulinum toxin type A (BoNTA) is a cornerstone in the
rapidly expanding ﬁeld of minimally invasive aesthetic
medicine. BoNTA’s safety and efﬁcacy, as well as its
recommendations for use in treating glabellar and other
facial lines, have been well documented in randomized
controlled trials, numerous clinical studies, and consensus
recommendations based on experts’ clinical experience [1–
4]. Nevertheless, the preponderance of this research has
been based on clinical trials involving female Caucasian
subjects. It is well recognized that ethnicity and skin color
are associated with variations in properties of facial skin
and musculature; therefore, it was deemed important to
establish the safety and efﬁcacy of BoNTA in Japanese
subjects in a systematic, well-controlled clinical trial.
Randomized controlled trials in predominantly Cauca-
sian populations have shown that 20-U doses of BoNTA
are effective and well tolerated in treating glabellar lines
[1–4]. A pilot study conducted in 125 Japanese subjects
showed similar results (unpublished data). The objectives
of this study were to conﬁrm and validate the effective dose
of this formulation of BoNTA (BOTOX
; Allergan, Inc.,
Irvine, CA) and characterize the efﬁcacy and safety proﬁle
in this patient population. This study included physician
assessments and subject-reported outcomes, which have
become increasingly recognized as key outcome measures
in aesthetic trials and clinical practice [5–8].
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Study Design
This multicenter, 16-week, double-blind, randomized,
placebo-controlled trial compared the efﬁcacy and safety of
two doses (10 and 20 U) of BoNTA versus placebo in
Japanese subjects with glabellar lines of at least moderate
severity at maximal contraction. This study was conducted
in compliance with the Declaration of Helsinki and the
Standards for the Implementation of Clinical Trials on
Pharmaceutical Products, and with the approval of the
institutional review boards of the participating centers. The
planned number of enrolled subjects was 135 (45 for each
of the three treatment groups).
Subjects
BoNTA-naı ¨ve patients aged 20–64 years with glabellar
lines of at least moderate severity at maximal contraction,
based on standardized photography, were eligible for the
study. Key exclusion criteria included any condition
(such as myasthenia gravis, Lambert-Eaton syndrome,
amyotrophic lateral sclerosis, or systemic neuromuscular
junction disorder) that could inﬂuence the effect of
treatment (e.g., deterioration in atonia); pregnancy; his-
tory of hypersensitivity to any component of the
treatment product; any condition that could impair the
safety of the subject (e.g., severe heart, kidney, liver, or
respiratory disease); infection or skin disease at the
injection site(s); use of a peripheral muscle relaxant
within 2 weeks of the start of the study; history of sur-
gery at the treatment site(s); or previous aesthetic
procedures within 6 months of the beginning of the study.
Subjects had to provide written informed consent after
receiving an explanation of the study. Discontinuation
criteria included voluntary retraction of consent, serious
clinical abnormality, unsuitability for evaluation, inability
to present for evaluation, protocol violation, or investi-
gator’s decision due to medical or nonmedical reasons.
Study Treatments
Active treatment was a 10- or 20-U dose of BoNTA sup-
plied in vials containing 100-U doses of BoNTA, 0.5 mg
albumin (human), and 0.9 mg sodium chloride. The pla-
cebo contained 0.9 mg sodium chloride only. Vials were
reconstituted with physiologic saline (Japanese Pharma-
copoeia) to deliver 2 or 4 U per site in equal volumes (total
of ﬁve injection sites of 2 or 4 U/0.1 ml/site) or an iden-
tical volume of placebo. Vials used for treatment
administration were coded to maintain the blind.
Study Procedures and Clinical Outcome Measures
Subjects meeting enrollment criteria provided a medical
history before enrollment and treatment, and females of
childbearing age had to have a negative pregnancy test.
Previous and concomitant therapies were documented.
Using the random-number-generation function of SAS
(Statistical Institute, Inc., Cary, NC), subjects were allo-
cated to one of three treatment groups: 10-U BoNTA, 20-U
BoNTA, or placebo. Vital signs and laboratory tests were
evaluated at pretreatment, week 4, week 16, and on the day
the subject discontinued.
Pretreatment line severity at rest and maximal contrac-
tion was assessed by a physician and photographed on the
day of treatment. Each subject then received two injections
in each corrugator supercilii muscle and one injection in
the procerus muscle for a total of ﬁve injection sites
(similar to other controlled trials of this formulation of
BoNTA) [3, 4]. The volume of each injection was 0.1 ml
for a total of 0.5 ml. Follow-up evaluations occurred at
week 1 and then at 4, 8, 12, and 16 weeks after treatment.
Each follow-up visit included a physician’s evaluation of
line severity at rest and maximal contraction, photographic
documentation, and the subject’s assessment of line
improvement. The measurement scales for assessing line
severity and improvement in line severity used the same
scoring as the Facial Wrinkle Scale and subject’s global
assessment of change in wrinkle appearance as the United
States pivotal trials [3, 4]. In addition, subjects rated their
degree of satisfaction with the effects of treatment at weeks
4 and 16 (Table 1). The week-16 satisfaction assessment
requested subjects to consider their satisfaction over the
period of the trial and whether they would like to be treated
again. Adverse events (AEs) were monitored throughout
the course of the study and assessed for severity and pos-
sible relationship to the treatment.
Efﬁcacy Endpoints and Statistical Analyses
The primary efﬁcacy endpoint was physician-rated line
severity 4 weeks after treatment at maximal contraction
(frown). Secondary endpoints included physician-assessed
line severity at maximal contraction at all other posttreat-
ment visits, line severity at rest at all visits, subject-
assessed improvement ratings at each visit, and patient
satisfaction ratings at weeks 4 and 16 and for the entire
study period (rated at week 16).
All patients randomized to treatment, except those with
severe protocol violations, comprised the full analysis set,
which was used for efﬁcacy analyses. The safety popula-
tion was composed of all subjects randomized to treatment
who received the trial substance at least once. Paired t tests
were used to analyze continuous variables for change-
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123from-baseline values. Analysis of variance was performed
for between-group comparisons. Nonparametric statistical
tests were conducted on categorical variables to analyze
changes from baseline and between-group differences. For
the primary efﬁcacy endpoint, responders were deﬁned as
those with posttreatment scores of 0 or 1. For the secondary
efﬁcacy endpoint, responders for line severity were deﬁned
as those with a score of 0 or 1, and responders for subject-
assessed improvement ratings were deﬁned as those with a
score of at least +2 (moderate improvement; deﬁnite
improvement, about 50% improvement). Duration of efﬁ-
cacy by group also was estimated. Subgroup analyses were
used to investigate the inﬂuence of baseline and subject
demographic variables on outcomes. Results were deemed
statistically signiﬁcant for p B 0.05.
Results
The full analysis data set comprised 140 patients (Fig. 1).
There were no statistically signiﬁcant differences among
the groups. Groups did not differ in their pretreatment line
severity either at rest or maximal contraction. The majority
of subjects were female (90.0%), and the mean age was
45.7 (±9.1) years. All subjects had either moderate
(50.7%) or severe (49.3%) glabellar lines at maximal
contraction. The safety population was 139 subjects: 46 in
the 10-U group, 44 in the 20-U group, and 49 in the pla-
cebo group. Six subjects in the full analysis data set
discontinued: two in the 20-U group discontinued before
treatment, two in the 10-U group moved away, one in the
20-U group retracted consent, and one in the placebo group
became pregnant.
Efﬁcacy
Physician Assessments
Primary Endpoint Response rates in each active-treatment
group differed signiﬁcantly from placebo but not from each
other. The response rates were 86.4% (38/44) in the 10-U
group, 88.6% (39/44) in the 20-U group, and 0% (0/48) in
the placebo group at week 4 posttreatment (Fig. 2).
Table 1 Clinical outcome measures—rating scales and deﬁnitions
Outcome measures Ratings, severity, and descriptions
Line severity, maximal contraction 3 = Severe; lines appear clearly formed. The bottoms of the deepest lines are
not visible from the surface.
2 = Moderate; lines appear clearly formed. The bottoms of the deepest lines are
visible from the surface.
1 = Mild; lines are noted
0 = None; lines are not noted
Line severity, at rest 3 = Lines are readily apparent
2 = Lines are noticeable
1 = Lines are somewhat noticeable
0 = Lines are not noticeable
Subject’s improvement assessment +4 = Complete improvement (about 100% improvement)
+3 = Marked improvement (substantial improvement, about 75% improvement)
+2 = Moderate improvement (deﬁnite improvement, about 50% improvement)
+1 = Slight improvement (some improvement, about 25% improvement)
0 = Unchanged
-1 = Slight worsening (about 25% worse)
-2 = Moderate worsening (about 50% worse)
-3 = Marked worsening (about 75% worse)
-4 = Very marked worsening (about 100% worse or greater)
Subject’s satisfaction assessment; degree of satisfaction
with the effects of treatment
1 = Very satisﬁed
2 = Satisﬁed
3 = Somewhat satisﬁed
4 = Indifferent
5 = Somewhat dissatisﬁed
6 = Dissatisﬁed
7 = Very dissatisﬁed
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123Secondary Endpoints Each active-treatment group
showed signiﬁcant improvements in line severity at maxi-
mal contraction relative to baseline ratings (p\0.001), in
contrast to the placebo group, which did not improve. The
percentage of responders (line severity none or mild at
maximal contraction) at each visit is shown in Fig. 2. Each
active-treatment group differed signiﬁcantly from placebo
at each visit (p\0.001) but did not differ from each other,
although the higher dose resulted in a somewhat higher
response rate that was sustained over the course of the
study, especially from week 8 onward. The degree of mean
change from baseline in line severity at maximal contrac-
tion also differed signiﬁcantly between the active-treatment
groups and placebo (p\0.001), but the active groups
again did not differ from each other (Fig. 3).
At rest, patterns of response were similar to those at
maximal contraction. The 10-U and 20-U BoNTA groups
differed signiﬁcantly from placebo (p\0.05) but not from
each other. The peak response rates in the active-treatment
groups occurred at week 4 for the 10-U group (84.1%) and
at weeks 4 and 8 for the 20-U group (93.2%). The 20-U
group differed from the placebo group at all visits
(p\0.05). The degree of change at rest was not as dra-
matic as at maximal contraction, in part because the
majority of subjects in each group (62.2, 52.3, and 69.4%
of 10-U, 20-U, and placebo groups, respectively) had
baseline scores of 0 (lines are not noticeable) or 1 (lines are
somewhat noticeable). The greatest proportion of subjects
whose lines at rest improved by at least one level occurred
at week 8 in the 20-U group (68.2%). The greatest pro-
portion of subjects with a similar level of improvement in
the 10-U group was 56.8% at week 4. The active-treatment
groups differed signiﬁcantly from placebo throughout the
study period (p\0.001) and from each other at week 8
(p = 0.021), at which time the 20-U group had a greater
degree of change.
Because of the high proportion of subjects with baseline
resting scores of B1, a subgroup analysis of subjects with
scores of C2 was performed (Fig. 4). This comprised a
total of 53 subjects: 17 in the 10-U group, 21 in the 20-U
group, and 15 in the placebo group. In this analysis, the 20-
U dose resulted in higher levels of improvement through-
out the study. The 10-U and 20-U groups differed
signiﬁcantly from placebo (p\0.019 and p\0.001,
respectively) and each other at week 8 (p = 0.037).
Subject Assessments
Line Improvement and Responder Rates At each post-
treatment visit subject assessment of line improvement was
signiﬁcantly greater (p\0.001) than placebo for each of
Screened and randomized
to double-blind trial
N=142
20 U 10 U Placebo
n=46 n=45
Pretreatment
N=140 n=49
n=44 n=45
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Week 1
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N=136
n=48
n=44 n=43
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Week 8
N=135
n=48
n=44 n=42
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Posttreatment
Week 16
N=134
n=48
Fig. 1 Study design and patient ﬂow through study
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123the two active-treatment groups. Moreover, the 20-U group
differed signiﬁcantly from the 10-U group at week 8
(p = 0.001). The percentage of responders (subject’s
improvement assessment of C+2) at each visit demon-
strated that both active treatments consistently resulted in a
signiﬁcantly (p\0.001) greater proportion of responders
than placebo (Fig. 5). In addition, the 20-U treatment
resulted in a signiﬁcantly (p = 0.035) greater proportion of
responders at week 8 than did the 10-U treatment.
Subject Satisfaction Ratings Subjects treated with BoN-
TA had signiﬁcantly higher satisfaction scores than those
treatedwithplaceboatbothevaluationtimepointsaswellas
for the entire study period (p\0.001). The satisfaction
ratings did not differ signiﬁcantly between the two active-
treatment groups at any time point. The proportions of sub-
jects who rated themselves as at least somewhat satisﬁed
(scores of 1, 2, or 3) are shown in Fig. 6. In the two active-
treatmentgroups,meansatisfactionratingscorespeakedat4
weeksat2.2(where1isverysatisﬁed)forthe10-Ugroupand
at 2.1 for the 20-U group. At 16 weeks, the scores were 3.5
and 3.2, respectively, and for the entire observation period
they were 2.5 and 2.1, respectively. Analysis of covariates
indicated thatatweek4,doseofBoNTA,lineseverityrating
during maximal contraction and at resting position (both
with baseline level subtracted), and subject-assessed line
improvement were signiﬁcantly (p\0.001) related to sub-
jectsatisfaction.Analysesoftheweek-16 dataindicatedthat
in addition to the preceding variables, the subjects’ gender
and age were associated with satisfaction. Speciﬁcally,
female sex and increasing age were associated with a lower
probabilityofsatisfaction.Analysisoftheentireobservation
period resulted in similar ﬁndings; however, the subject’s
gender did not have an effect on subject satisfaction. Age
remained the only variable with an upper conﬁdence limit of
\1, indicating a decreasing probability of satisfaction with
advancing age.
Duration of Effect
The duration of BoNTA’s effect was based on the change
in line severity at maximal contraction from week 1 to
week 16 posttreatment. The treatment was determined to
remain effective for the amount of time during which line
severity at maximal contraction was 0 (none) or 1 (mild),
not on return to baseline levels of severity. The mean
duration of effect was 9.4 weeks for the 20-U treatment
group and 7.9 weeks for the 10-U group. The analysis of
duration for 10-U and 20-U groups by the Kaplan–Meier
curve is shown in Fig. 7.
Safety and Tolerability
No subject discontinued the study because of an adverse
effect (AE). Neither the incidence of AEs nor that of
adverse drug reactions (ADRs) differed signiﬁcantly
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123between groups. The incidence of AEs was 67.4% (31/46)
in the 10-U group, 75.0% (33/44) in the 20-U group, and
59.2% (29/49) in the placebo group. The rate of ADRs was
32.6% in the 10-U group, 27.3% in the 20-U group, and
22.4% in the placebo group. There were no deaths, nor any
serious AEs requiring emergency interventions. Of the 139
subjects, 2 developed blepharoptosis (1 in each active-
treatment group), and 12 experienced heavy eyelids (5 in
the 10-U group, 6 in the 20-U group, and 1 in the placebo
group). Each of these events was mild in severity and
resolved over the course of the study.
Discussion
This study conﬁrms the utility of BoNTA for the treatment
of glabellar lines and demonstrates its safety and efﬁcacy in
Japanese subjects. Doses of 10 U and 20 U were effective
in treating glabellar lines based on both physician and
subject ratings. BoNTA treatment resulted in signiﬁcant
improvement of line severity at both maximal contraction
and rest, which is consistent with previous controlled
clinical trials of this formulation [9]. Subjects rated their
satisfaction with treatment as high at weeks 4 and 16, and
for the entire study period. Overall duration of effect in this
study also was similar to that of earlier studies.
The overall results of this study indicate that the two
doses of BoNTA did not differ signiﬁcantly on several of
the endpoints but suggest that the 20-U dose may provide
somewhat higher response levels, greater improvement
from baseline, and a somewhat longer duration of effect, as
measured by between-group differences at the various time
points. This study did not assess the absolute duration of
effect because relapse rates (return to pretreatment line
severity) were not included. Also, as all subjects in this
study were naı ¨ve to BoNTA treatment, repeated treatment
without dosing changes could perhaps extend the duration
of beneﬁt or result in progressive improvement [1, 10, 11].
The ﬁndings of this study are consistent with those of
other studies in which responses appear to be dose
dependent but which were not always statistically signiﬁ-
cant [9, 12]. In the present study, only two doses were used,
both of which were effective overall. These ﬁndings,
coupled with the subgroup and covariate analyses, suggest
that fruitful areas for additional research include the impact
on efﬁcacy and the interaction of variables such as age,
gender, BoNTA dose, and pretreatment line severity.
Conclusions
Doses of 10 U and 20 U of BoNTA are effective and well
tolerated in treating glabellar lines in Japanese subjects;
however, the 20-U dose provides greater efﬁcacy and a
somewhat longer duration of effect than does the 10-U dose.
Note These results do not apply to any formulation of
BoNTA other than that used in the present study, due to
well-documented differences in formulations and lack of
interchangeability [13, 14]. It should be noted that the
results reported in this study refer to the Allergan (Irvine,
CA, USA) formulation of BoNTA (BOTOX
, BOTOX

Cosmetic, Vistabel
) and cannot be generalized to other
formulations or serotypes of botulinum toxin.
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